ism, and the prevention of systemic embolization. Most of the others were aiming for INR ratios in the range of 1.5-4.5. The recommended therapeutic range for warfarin therapy in the treatment of deep venous thrombosis and pulmonary embolism, and the prevention of systemic embolism, is 2-3, but this figure is based on few trials. Although 34% ofINR values accepted as being satisfactory by the junior doctors were below the lower level of the recommended range, none of these patients had recurrence of their condition. Although 19% of the INR values were above the upper limit of the recommended ratio, no complication of overanticoagulation was noted in this group of 50 patients. Patients were maintained outside the recommended INR range despite the therapeutic level being printed on the pathology reports.
We suggest first, in the short term, that hospital doctors should be made aware of the present recommended therapeutic range of INR; and second, that the therapeutic range recommended in the United Kingdom needs to be further evaluated. Patients and methods There were 19 men and 31 women of mean age 74.8 years (range 28--82) in a consecutive series of 50 hospitals inpatients' who had been prescribed warfarin for deep vein thrombosis (22), pulmonary embolism (12),atrial fibrillation and valvular heart disease (14), and left ventricular mural thrombus following myocardial infarction (2). After treatment with warfarin had been stabilized (i.e, INR 2-3), the INR was checked, on average, once a week. All patients were followed over a period of six months. Twenty-two junior hospital doctors were interviewed in order to ascertain their accepted therapeutic range when using warfarin for the indications listed above.
Summary
Anticoagulation control in hospital inpatients was monitored in a prospective study. Only 47% of the blood results were within the therapeutic range which is presently recommended.
Introduction
The International Normalized Ratio (INR) is a system for reporting prothrombin times recommended by the WHO. The current recommendation from the British Society ofHaematology for the treatment of proximal deep venous thrombosis and pulmonary embolism, and the prevention of systemic embolism in patients with atrial fibrillation, valvular heart disease, tissue heart valves or acute myocardial infarction, is that the therapeutic range for oral warfarin is equivalent to a standard INR of2.G-3.0 1 • This recommendation for venous thrombosis and pulmonary embolism is based on the results of only one clinical trial", The recommendation for myocardial infarction is based on only two studies':".
In a previous study' in which outpatient anticoagulation therapy was monitored, it was shown that outpatient anticoagulation control in the UK was poor. Our clinical impression was that many patients prescribed warfarin in hospital were not maintained within this recommended therapeutic range. We therefore prospectively monitored the anticoagulation control of a series of hospital inpatients. Figure 1 illustrates 156 INR values in 50 patients during their hospital stay following initial stabilization with warfarin. Less than half (47%) were in the recommended ratio of2-3, 34% were less than 2, and 19% were greater than 3. Over a period of six months none of the patients suffered either from recurrence of their condition due to under-anticoagulation, or from bleeding from over-anticoagulation.
Results
Only 4 of 22 junior doctors were aware of the recommended INR ratio of 2-3 for the treatment of proximal deep vein thrombosis and pulmonary embol-
